NCT05685602 2026-03-18
CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer
National Cancer Institute (NCI)
Phase 1 Recruiting
Clinical Trials
51 trialsNCT07481383 2026-03-18
A First-in-Human Study to Evaluate Implantable Iontophoresis Chemotherapy Delivery Device With Gemcitabine Once Weekly or Twice Weekly in Participants With Pancreatic Cancer
Continuity Biosciences, LLC
Phase 1 Recruiting
NCT07223047 2026-03-17
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
Bristol-Myers Squibb
Phase 1/2 Recruiting
NCT06445062 2026-03-13
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Revolution Medicines, Inc.
Phase 1/2 Recruiting
NCT07020221 2026-03-09
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Verastem, Inc.
Phase 1/2 Recruiting
NCT04683315 2026-03-05
PANCREAS
Medical College of Wisconsin
Phase 2 Recruiting
NCT06953999 2026-03-04
A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer
Akeso
Phase 3 Recruiting
NCT06998940 2026-02-20
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
SWOG Cancer Research Network
Phase 3 Recruiting
NCT06360354 2026-02-12
MTAPESTRY 103
Amgen
Phase 1 Recruiting
NCT06958328 2026-02-02
LAP100
NRG Oncology
Phase 3 Recruiting
NCT06951997 2026-01-26
QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting
NCT07255404 2026-01-09
A Clinical Trial Testing the Safety of BNT327 (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer
BioNTech SE
Phase 2 Recruiting
NCT03322995 2026-01-08
PANC
Medical College of Wisconsin
Phase 2 Recruiting
NCT06361888 2025-12-30
A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer
Hutchmed
Phase 2/3 Recruiting
NCT07226856 2025-12-22
BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma
Mayo Clinic
Phase 2 Recruiting
NCT06584227 2025-12-08
ACPC
Jinling Hospital, China
Phase 2 Recruiting
NCT06783140 2025-12-05
PLATINUM-CAN
University Health Network, Toronto
Phase 2/3 Recruiting
NCT07043270 2025-10-20
24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC
Dartmouth-Hitchcock Medical Center
Phase 2 Recruiting
NCT06770452 2025-09-23
HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients
Zhejiang University
Phase 2 Recruiting
NCT07079228 2025-09-23
A Study to Compare QLS31905 and Chemotherapy With Placebo and Chemotherapy in Participants With Pancreatic Cancer
Qilu Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT06767813 2025-09-19
Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Recruiting
NCT06313970 2025-09-03
First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients
Fudan University
Phase 2 Recruiting
NCT06423326 2025-07-30
Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer
Emory University
Phase 2 Recruiting
NCT05451043 2025-06-26
Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)
AHS Cancer Control Alberta
Phase 2 Recruiting
NCT04543071 2025-06-19
Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma
Columbia University
Phase 2 Recruiting
NCT05241249 2025-06-05
Stimulation With Bethanechol in Combination With Gemcitabine and Nab-paclitaxel in Pancreatic Adenocarcinoma
Columbia University
Phase 2 Recruiting
NCT05141149 2025-06-04
First in Human Phase1/2a Clinical Trial of Anti-PAUF Monoclonal Antibody PBP1510 in Patients With Pancreatic Cancer
Prestige Biopharma Limited
Phase 1/2 Recruiting
NCT04894643 2025-05-08
PARC
EBG MedAustron GmbH
Phase NA Recruiting
NCT05827796 2025-04-30
IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer
InxMed (Shanghai) Co., Ltd.
Phase 1/2 Recruiting
NCT06483555 2025-04-16
PANGEA
UNC Lineberger Comprehensive Cancer Center
Phase 1/2 Recruiting
NCT05984602 2025-04-15
A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer
NYU Langone Health
Phase 1 Recruiting
NCT06454383 2025-04-10
Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer
City of Hope Medical Center
Phase 1 Recruiting
NCT05776524 2025-03-25
Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer
THERABIONIC INC.
Phase 2 Recruiting
NCT03579836 2025-03-10
Evaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient with Pancreatic Cancer
BeyondBio Inc.
Phase 1/2 Recruiting
NCT05841420 2025-01-29
Gemcitabine Versus Reduced-dose Combination Chemotherapy in Fragile Patients with Non-resectable Pancreatic Cancer
Aalborg University Hospital
Phase 2 Recruiting
NCT05218889 2024-12-31
Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer
Chinese PLA General Hospital
Phase 1/2 Recruiting
NCT06639724 2024-12-27
Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer
University of California, San Diego
Phase 1 Recruiting
NCT05859750 2024-12-16
A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer
Akeso
Phase 2 Recruiting
NCT05254171 2024-11-06
ASPIRE
Panbela Therapeutics, Inc.
Phase 2/3 Recruiting
NCT06539806 2024-08-06
Clinical Study Evaluating the Effect of Losartan
Tanta University
Phase NA Recruiting
NCT06491472 2024-07-09
Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Recruiting
NCT06359275 2024-06-25
PD-1 Combined With Chemotherapy and PULSAR in LAPC and Local Recurrence Patients
Fudan University
Phase 2 Recruiting
NCT06030622 2024-04-19
C3
State University of New York - Downstate Medical Center
Phase 1/2 Recruiting
NCT05064618 2024-04-04
MIKE-1
Nagoya University
Phase 1/2 Recruiting
NCT03721744 2024-04-03
A Study of GB201 in Combination With Weekly Paclitaxel and Low-dose Gemcitabine in Patients With Pancreatic Cancer
1Globe Biomedical Co., Ltd.
Phase 2/3 Recruiting
NCT05048524 2024-03-27
Peri-operative SLOG for Localized Pancreatic Cancer
National Health Research Institutes, Taiwan
Phase 2 Recruiting
NCT06017284 2023-11-24
PTCA199-5
Fudan University
Phase 3 Recruiting
NCT05733000 2023-03-10
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
Northwestern University
Phase 2 Recruiting
NCT04969731 2021-11-22
Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer
GC Cell Corporation
Phase 3 Recruiting
NCT05035147 2021-09-21
Albumin-bound Paclitaxel Combined With Gemcitabine First-line Inoperable Pancreatic Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 4 Recruiting